Regulation of Myeloid Dendritic Cells by Synthetic and Natural Compounds for the Treatment of Rheumatoid Arthritis.
Hira UmbreenXiang ZhangKuo-Tung TangChi-Chien LinPublished in: International journal of molecular sciences (2022)
Different subsets of dendritic cells (DCs) participate in the development of rheumatoid arthritis (RA). In particular, myeloid DCs play a key role in the generation of autoreactive T and B cells. Herein, we undertook a literature review on those synthetic and natural compounds that have therapeutic efficacy/potential for RA and act through the regulation of myeloid DCs. Most of these compounds inhibit both the maturation of DCs and their secretion of inflammatory cytokines and, subsequently, alter the downstream T-cell response (suppression of Th1 and Th17 responses while expanding the Treg response). The majority of the synthetic compounds are approved for the treatment of patients with RA, which is consistent with the importance of DCs in the pathogenesis of RA. All of the natural compounds are derived from plants. Their DC-modulating effect has been demonstrated both in vitro and in vivo. In addition, these natural products ameliorate arthritis in rodents and are potential therapeutics for human RA.
Keyphrases
- rheumatoid arthritis
- dendritic cells
- disease activity
- immune response
- ankylosing spondylitis
- regulatory t cells
- interstitial lung disease
- bone marrow
- endothelial cells
- systemic lupus erythematosus
- case report
- acute myeloid leukemia
- small molecule
- peripheral blood
- idiopathic pulmonary fibrosis
- induced pluripotent stem cells
- drug administration